By: Sara Riascos  May. 16, 2022

Dexur’s analysis of Real World Evidence based on Medicare Claims data showed that the use of Bumetanide within 7 days of hospitalization was associated with lower hospital readmission rates for Heart Failure Patients at AdventHealth Orlando in Orlando, Florida. Reduction in readmission rates helps hospitals improve their outcomes for various cost and quality programs. Dexur is an approved entity to perform Medicare claims data analysis, which it uses to perform quality outcomes analysis. Dexur has published several papers with Harvard Medical School on quality outcomes related topics. Dexur’s analysis of drugs and their impact on quality outcomes, such as readmissions and mortality, are used by Hospitals, IDNs, and ACOs to implement best practices and manage Real World Evidence based risk factors.